EGFR and non-small cell lung carcinoma: Garofalo et al. reported that miR-30b-c and 221-222 are involved in gefitinib, an EGFR inhibitor, resistance of NSCLC cells by modulating APAF-1 and BIM (Garofalo et al., 2011).